Stockscreener 앱 받기
25.85
1.30%
-0.34
시간 외 거래:
26.20
0.35
+1.35%
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
See How Institutions Boost Catalyst Shares - Yahoo Finance Australia
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Strength - Yahoo Finance
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with a Positive Technical Setup - ChartMill
Gains Recap: Is Catalyst Pharmaceuticals Incs growth already priced inMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Jim Cramer on Catalyst Pharmaceuticals: "It's a very inexpensive stock" - MSN
If You Invested $1000 in Catalyst Pharmaceutical 10 Years Ago, This Is How Much You'd Have Now - qz.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView — Track All Markets
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock - ChartMill
Price Action: Will Catalyst Pharmaceuticals Inc benefit from government policy2026 Trading Volume Trends & Reliable Price Breakout Signals - baoquankhu1.vn
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know - TradingView — Track All Markets
(CPRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum - Sahm
Bear Alert: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Extending Firdapse Exclusivity And Launching AgamreeHas The Bull Case Changed? - Yahoo Finance
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView — Track All Markets
Catalyst Pharmaceuticals, Inc. (CPRX) stock price, news, quote and history - Yahoo Finance UK
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - The Globe and Mail
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is It Too Late To Consider Catalyst Pharmaceuticals (CPRX) After Strong Multi Year Rerating? - Sahm
Catalyst Pharmaceuticals, Inc. (CPRX) latest stock news and headlines - Yahoo Finance Australia
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study - TradingView — Track All Markets
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Forecasts - Yahoo Finance
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - TradingView
Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability? - Yahoo Finance
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
JPMorgan Chase & Co. Sells 54,915 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
New Strong Buy Stocks for March 31st - Yahoo Finance Singapore
Best Value Stocks to Buy for March 31st - Yahoo Finance Singapore
Aug Movers: Can Catalyst Pharmaceuticals Inc stock outperform in a bear marketEarnings Recap Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Trading And DCF Upside Signals - Yahoo Finance
Aug Mood: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Market Sentiment & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Mixed Long Term And Recent Shareholder Returns - Sahm
Insider Buy: Is Catalyst Pharmaceuticals Inc currently under institutional pressure2026 Fundamental Recap & Long-Term Investment Growth Plans - baoquankhu1.vn
(CPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Total Market Plus Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Analysts see big upside in Catalyst Pharmaceuticals, Inc. (CPRX) - MSN
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes - TradingView
Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Strong Buy" by Brokerages - MarketBeat
Vanguard realigns reporting; Catalyst Pharmaceuticals (CPRX) shows 0% ownership - Stock Titan
Truist Financial Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to "Strong-Buy" - MarketBeat
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
2.69%
0.25%
자본화:
|
볼륨(24시간):